Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-
4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic …

Most patients with BRAF V600-mutant metastatic melanoma develop resistance to selective
RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF …

Facing the increasing number of melanoma patients is the controversial question of whether
an incisional biopsy is associated with an unfavorable patient prognosis. Results of nine …

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study …

Enhancing immune responses with immune-modulatory monoclonal antibodies directed to
inhibitory immune receptors is a promising modality in cancer therapy. Clinical efficacy has …

Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as
these may influence individual treatment selection or sequence. We aimed to identify …

Purpose: To identify baseline peripheral blood biomarkers associated with clinical outcome
following ipilimumab treatment in advanced melanoma patients. Experimental Design …

Tumor cells (over-) express specific antigens which allow them to be recognized and
destroyed by the immune system. Triggering anti-tumor immunity in cancer patients by …

In mice, injection of messenger RNA (mRNA) coding for tumor-associated antigens can
induce antitumor immune responses and therefore offers a broadly applicable …

Vaccination against tumor antigens has been shown to be a safe and efficacious
prophylactic and therapeutic antitumor treatment in many animal models. Clinical studies in …